Skip to main content
Top
Published in: Tumor Biology 10/2016

01-10-2016 | Original Article

Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma

Authors: Elisa Lappi-Blanco, Johanna M. Mäkinen, Siri Lehtonen, Henna Karvonen, Raija Sormunen, Kirsi Laitakari, Shirley Johnson, Riitta Mäkitaro, Risto Bloigu, Riitta Kaarteenaho

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

Mucin-1 (MUC1) affects cancer progression in lung adenocarcinoma, and its aberrant expression pattern has been correlated with poor tumor differentiation and impaired prognosis. In this study, the immunohistochemical expression of MUC1 and Mucin-4 (MUC4) was analyzed in a series of 106 surgically operated stage I–IV pulmonary adenocarcinomas. MUC1 immunohistochemistry was evaluated according to the Nagai classification, and the immunohistochemical profile of the tumors was correlated with detailed clinical and histological data. The effect of cigarette smoke on MUC1 expression in lung cancer cell lines was examined using real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) and immunoelectron microscopy (IEM). In contrast to the normal apical localization of MUC1, a basolateral and cytoplasmic (depolarized) MUC1 expression pattern was frequently encountered in the high-grade subtypes, i.e., solid predominant adenocarcinoma and the cribriform variant of acinar predominant adenocarcinoma (p < 0.001), and was rarely observed in tumors containing a non-predominant lepidic component (p < 0.001). Furthermore, the altered staining pattern of MUC1 correlated with stage (p = 0.002), reduced overall survival (p = 0.031), and was associated with smoking (p < 0.001). When H1650 adenocarcinoma cells were exposed to cigarette smoke and analyzed by RT-qPCR and IEM, the levels of the MUC1 transcript and protein were elevated (p = 0.042). In conclusion, MUC1 participates in the pathogenesis of lung adenocarcinoma and associates with smoking both in vitro and in vivo. In lung adenocarcinoma, depolarized MUC1 protein expression correlated with histological growth patterns, stage, and patient outcome.
Literature
1.
go back to reference Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29:2893–904.CrossRefPubMedPubMedCentral Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29:2893–904.CrossRefPubMedPubMedCentral
2.
go back to reference Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol. 1988;18:203–16.PubMed Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol. 1988;18:203–16.PubMed
3.
go back to reference Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer. 1984;34:197–206.CrossRefPubMed Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer. 1984;34:197–206.CrossRefPubMed
4.
go back to reference Jarrard JA, Linnoila RI, Lee H, Steinberg SM, Witschi H, Szabo E. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res. 1998;58:5582–9.PubMed Jarrard JA, Linnoila RI, Lee H, Steinberg SM, Witschi H, Szabo E. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res. 1998;58:5582–9.PubMed
5.
go back to reference Ohgami A, Tsuda T, Osaki T, et al. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg. 1999;67:810–4.CrossRefPubMed Ohgami A, Tsuda T, Osaki T, et al. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg. 1999;67:810–4.CrossRefPubMed
6.
go back to reference Guddo F, Giatromanolaki A, Patriarca C, et al. Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. Anticancer Res. 1998;18:1915–20.PubMed Guddo F, Giatromanolaki A, Patriarca C, et al. Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. Anticancer Res. 1998;18:1915–20.PubMed
7.
go back to reference Zhang L, Gallup M, Zlock L, Basbaum C, Finkbeiner WE, McNamara NA. Cigarette smoke disrupts the integrity of airway adherens junctions through the aberrant interaction of p120-catenin with the cytoplasmic tail of MUC1. J Pathol. 2013;229:74–86.CrossRefPubMed Zhang L, Gallup M, Zlock L, Basbaum C, Finkbeiner WE, McNamara NA. Cigarette smoke disrupts the integrity of airway adherens junctions through the aberrant interaction of p120-catenin with the cytoplasmic tail of MUC1. J Pathol. 2013;229:74–86.CrossRefPubMed
8.
go back to reference Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H, Tanaka F. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol. 2006;1:46–51.PubMed Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H, Tanaka F. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol. 2006;1:46–51.PubMed
9.
go back to reference Lakshmanan I, Ponnusamy MP, Macha MA, et al. Mucins in lung cancer: diagnostic, prognostic, and therapeutic implications. J Thorac Oncol. 2015;10:19–27.CrossRefPubMed Lakshmanan I, Ponnusamy MP, Macha MA, et al. Mucins in lung cancer: diagnostic, prognostic, and therapeutic implications. J Thorac Oncol. 2015;10:19–27.CrossRefPubMed
10.
go back to reference Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res. 2000;6:1917–21.PubMed Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res. 2000;6:1917–21.PubMed
11.
go back to reference Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med. 2000;161:589–94.CrossRefPubMed Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med. 2000;161:589–94.CrossRefPubMed
12.
go back to reference Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Yonezawa S. Combined status of MUC1 mucin and surfactant apoprotein a expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology. 2004;44:147–55.CrossRefPubMed Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Yonezawa S. Combined status of MUC1 mucin and surfactant apoprotein a expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology. 2004;44:147–55.CrossRefPubMed
13.
go back to reference Fujiwara Y, Kiura K, Toyooka S, et al. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer. 2008;59:81–7.CrossRefPubMed Fujiwara Y, Kiura K, Toyooka S, et al. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer. 2008;59:81–7.CrossRefPubMed
14.
go back to reference Ishikawa N, Hattori N, Yokoyama A, et al. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer. 2008;122:2612–20.CrossRefPubMed Ishikawa N, Hattori N, Yokoyama A, et al. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer. 2008;122:2612–20.CrossRefPubMed
15.
go back to reference Woenckhaus M, Merk J, Stoehr R, et al. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol. 2008;39:126–36.CrossRefPubMed Woenckhaus M, Merk J, Stoehr R, et al. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol. 2008;39:126–36.CrossRefPubMed
16.
go back to reference Situ D, Wang J, Ma Y, et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 2011;28(Suppl 1):S596–604.CrossRefPubMed Situ D, Wang J, Ma Y, et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 2011;28(Suppl 1):S596–604.CrossRefPubMed
17.
go back to reference Tanaka S, Hattori N, Ishikawa N, et al. Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer. Int J Cancer. 2012;130:377–87.CrossRefPubMed Tanaka S, Hattori N, Ishikawa N, et al. Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer. Int J Cancer. 2012;130:377–87.CrossRefPubMed
18.
go back to reference Kaira K, Nakagawa K, Ohde Y, et al. Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer. Int J Surg Pathol. 2012;20:223–32.CrossRefPubMed Kaira K, Nakagawa K, Ohde Y, et al. Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer. Int J Surg Pathol. 2012;20:223–32.CrossRefPubMed
19.
go back to reference Li J, YM H, YJ D, et al. Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer. BMC Cancer. 2014;14(848). doi:10.1186/1471-2407-14-848. Li J, YM H, YJ D, et al. Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer. BMC Cancer. 2014;14(848). doi:10.​1186/​1471-2407-14-848.
20.
go back to reference Zhu WF, Li J, LC Y, et al. Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients. Tumour Biol. 2014;35:1211–9.CrossRefPubMed Zhu WF, Li J, LC Y, et al. Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients. Tumour Biol. 2014;35:1211–9.CrossRefPubMed
21.
go back to reference Chen YT, Gallup M, Nikulina K, et al. Cigarette smoke induces epidermal growth factor receptor-dependent redistribution of apical MUC1 and junctional beta-catenin in polarized human airway epithelial cells. Am J Pathol. 2010;177:1255–64.CrossRefPubMedPubMedCentral Chen YT, Gallup M, Nikulina K, et al. Cigarette smoke induces epidermal growth factor receptor-dependent redistribution of apical MUC1 and junctional beta-catenin in polarized human airway epithelial cells. Am J Pathol. 2010;177:1255–64.CrossRefPubMedPubMedCentral
22.
go back to reference Xu X, Bai L, Chen W, et al. MUC1 contributes to BPDE-induced human bronchial epithelial cell transformation through facilitating EGFR activation. PLoS One. 2012;7:e33846.CrossRefPubMedPubMedCentral Xu X, Bai L, Chen W, et al. MUC1 contributes to BPDE-induced human bronchial epithelial cell transformation through facilitating EGFR activation. PLoS One. 2012;7:e33846.CrossRefPubMedPubMedCentral
23.
go back to reference Zhang L, Gallup M, Zlock L, Chen YT, Finkbeiner WE, McNamara NA. Pivotal role of MUC1 glycosylation by cigarette smoke in modulating disruption of airway adherens junctions in vitro. J Pathol. 2014;234:60–73.CrossRefPubMedPubMedCentral Zhang L, Gallup M, Zlock L, Chen YT, Finkbeiner WE, McNamara NA. Pivotal role of MUC1 glycosylation by cigarette smoke in modulating disruption of airway adherens junctions in vitro. J Pathol. 2014;234:60–73.CrossRefPubMedPubMedCentral
24.
go back to reference Xu X, Padilla MT, Li B, et al. MUC1 in macrophage: contributions to cigarette smoke-induced lung cancer. Cancer Res. 2014;74:460–70.CrossRefPubMed Xu X, Padilla MT, Li B, et al. MUC1 in macrophage: contributions to cigarette smoke-induced lung cancer. Cancer Res. 2014;74:460–70.CrossRefPubMed
25.
go back to reference Ishikawa N, Mazur W, Toljamo T, et al. Ageing and long-term smoking affects KL-6 levels in the lung, induced sputum and plasma. BMC Pulm Med. 2011;11:22 .2466-11-22CrossRefPubMedPubMedCentral Ishikawa N, Mazur W, Toljamo T, et al. Ageing and long-term smoking affects KL-6 levels in the lung, induced sputum and plasma. BMC Pulm Med. 2011;11:22 .2466-11-22CrossRefPubMedPubMedCentral
26.
go back to reference Hanaoka J, Kontani K, Sawai S, et al. Analysis of MUC4 mucin expression in lung carcinoma cells and its immunogenicity. Cancer. 2001;92:2148–57.CrossRefPubMed Hanaoka J, Kontani K, Sawai S, et al. Analysis of MUC4 mucin expression in lung carcinoma cells and its immunogenicity. Cancer. 2001;92:2148–57.CrossRefPubMed
27.
go back to reference Karg A, Dinc ZA, Basok O, Ucvet A. MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC). Pathol Res Pract. 2006;202:577–83.CrossRefPubMed Karg A, Dinc ZA, Basok O, Ucvet A. MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC). Pathol Res Pract. 2006;202:577–83.CrossRefPubMed
28.
go back to reference Kwon KY, Ro JY, Singhal N, et al. MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival. Arch Pathol Lab Med. 2007;131:593–8.PubMed Kwon KY, Ro JY, Singhal N, et al. MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival. Arch Pathol Lab Med. 2007;131:593–8.PubMed
29.
go back to reference Tsutsumida H, Goto M, Kitajima S, et al. MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer. 2007;55:195–203.CrossRefPubMed Tsutsumida H, Goto M, Kitajima S, et al. MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer. 2007;55:195–203.CrossRefPubMed
30.
go back to reference Majhi PD, Lakshmanan I, Ponnusamy MP, et al. Pathobiological implications of MUC4 in non-small-cell lung cancer. J Thorac Oncol. 2013;8:398–407.CrossRefPubMed Majhi PD, Lakshmanan I, Ponnusamy MP, et al. Pathobiological implications of MUC4 in non-small-cell lung cancer. J Thorac Oncol. 2013;8:398–407.CrossRefPubMed
31.
go back to reference Gao L, Liu J, Zhang B, et al. Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Tumour Biol. 2014;35:1335–41.CrossRefPubMed Gao L, Liu J, Zhang B, et al. Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Tumour Biol. 2014;35:1335–41.CrossRefPubMed
32.
go back to reference Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC; 2015. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC; 2015.
33.
go back to reference Makinen JM, Laitakari K, Johnson S, et al. Nonpredominant lepidic pattern correlates with better outcome in invasive lung adenocarcinoma. Lung Cancer. 2015;90:568–74.CrossRefPubMed Makinen JM, Laitakari K, Johnson S, et al. Nonpredominant lepidic pattern correlates with better outcome in invasive lung adenocarcinoma. Lung Cancer. 2015;90:568–74.CrossRefPubMed
34.
go back to reference Rusch VW, Appleman HD, Blackstone E, et al. Lung. In: Edge SB, Byrd DR, Compton C.C., Fritz A.G., Greene FL, Trotti A, editors. AJCC Cancer Staging Handbook from the AJCC Cancer Staging Manual. Seventh ed. Springer, 2010. p. 299–323. Rusch VW, Appleman HD, Blackstone E, et al. Lung. In: Edge SB, Byrd DR, Compton C.C., Fritz A.G., Greene FL, Trotti A, editors. AJCC Cancer Staging Handbook from the AJCC Cancer Staging Manual. Seventh ed. Springer, 2010. p. 299–323.
35.
go back to reference Lee HJ, Xu X, Choe G, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer. 2010;68:375–82.CrossRefPubMed Lee HJ, Xu X, Choe G, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer. 2010;68:375–82.CrossRefPubMed
36.
go back to reference Merikallio H, Kaarteenaho R, Paakko P, et al. Impact of smoking on the expression of claudins in lung carcinoma. Eur J Cancer. 2011;47:620–30.CrossRefPubMed Merikallio H, Kaarteenaho R, Paakko P, et al. Impact of smoking on the expression of claudins in lung carcinoma. Eur J Cancer. 2011;47:620–30.CrossRefPubMed
37.
go back to reference Kaarteenaho-Wiik R, Paakko P, Sormunen R. Ultrastructural features of lung fibroblast differentiation into myofibroblasts. Ultrastruct Pathol. 2009;33:6–15.CrossRefPubMed Kaarteenaho-Wiik R, Paakko P, Sormunen R. Ultrastructural features of lung fibroblast differentiation into myofibroblasts. Ultrastruct Pathol. 2009;33:6–15.CrossRefPubMed
38.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMed Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMed
39.
go back to reference Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995;129:255–65.CrossRefPubMed Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995;129:255–65.CrossRefPubMed
40.
go back to reference Kharbanda A, Rajabi H, Jin C, et al. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res. 2014;20:5423–34.CrossRefPubMedPubMedCentral Kharbanda A, Rajabi H, Jin C, et al. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res. 2014;20:5423–34.CrossRefPubMedPubMedCentral
42.
go back to reference Yao M, Zhang W, Zhang Q, et al. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways. Lung. 2011;189:453–60.CrossRefPubMed Yao M, Zhang W, Zhang Q, et al. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways. Lung. 2011;189:453–60.CrossRefPubMed
43.
go back to reference Buisine MP, Devisme L, Copin MC, et al. Developmental mucin gene expression in the human respiratory tract. Am J Respir Cell Mol Biol. 1999;20:209–18.CrossRefPubMed Buisine MP, Devisme L, Copin MC, et al. Developmental mucin gene expression in the human respiratory tract. Am J Respir Cell Mol Biol. 1999;20:209–18.CrossRefPubMed
44.
go back to reference Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J. 2008;22:966–81.CrossRefPubMed Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J. 2008;22:966–81.CrossRefPubMed
Metadata
Title
Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma
Authors
Elisa Lappi-Blanco
Johanna M. Mäkinen
Siri Lehtonen
Henna Karvonen
Raija Sormunen
Kirsi Laitakari
Shirley Johnson
Riitta Mäkitaro
Risto Bloigu
Riitta Kaarteenaho
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5269-6

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine